GW50516 - Pharmaqo Labs

Developed as a treatment for metabolic syndrome, Cardarine (GW501516) was initially praised for its ability to reduce LDL cholesterol and stimulate fat oxidation. Its mechanism involves activating PPAR delta receptors, which promotes mitochondrial function and increases aerobic capacity. Although never approved for medical use, it gained traction in athletic circles for its stamina-boosting effects. However, animal studies raised alarms after showing tumor development in multiple tissues, casting a shadow over its potential despite ongoing use in research and bodybuilding .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about GW50516 by Pharmaqo Labs, consult with your doctor or healthcare professional.